Tucson, AZ, Nov 20, 2024, SynCardia Systems, LLC., a Picard Medical Inc. company, is proud to announce that it has surpassed the 2,100-patient mark of SynCardia Total Artificial Hearts implants.
SynCardia Total Artificial Hearts were implanted in Europe at the Dedinje Cardiovascular Institute in Belgrade, the Universitatsklinik der Ruhr-Heart Center NRW in Bad Oeyenhausen, and at the Center Hospitalier Universitaire de Nantes; in Canda at the Montreal Heart Institute; and at several US centers including implants at Banner University Medical Center in Phoenix, Cincinnati Children’s Hospital, C.S. Mott Children’s Hospital in Ann Arbor, and at
Mount Sinai Medical Center in New York City.
“The increasing number of patients implanted with the SynCardia Total Artificial Heart highlights the continued demand for our unique device, the world’s only US Food and Drug Administration-approved total artificial heart,” commented Patrick NJ Schnegelsberg, CEO. “We are grateful for the support of our team at SynCardia and the cardiovascular, surgical and MCS teams at numerous centers around the world implanting the SynCardia Total Artificial Heart. Saving Lives, One Heart at a Time!”
About SynCardia Systems, LLC
SynCardia Systems, LLC. is the leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart, which is the only U.S. Food and Drug Administration (FDA) and Health Canada (HC) approved artificial heart1.
SOURCE: SynCardia Systems, LLC
1. The SynCardia temporary Total Artificial Heart (the TAH-t) is indicated for use as a bridge to transplantation in cardiac transplant- eligible candidates at risk of imminent death from biventricular failure.